A new NIH-funded study published in Nature Aging has identified a groundbreaking approach to detecting Alzheimer’s disease through a simple blood test — one that reads the shape of proteins rather than just their quantity. Researchers say the technique could unlock earlier diagnosis, better staging of the disease, and more effective clinical trials.
The Problem With Current Alzheimer’s Blood Tests
Most existing blood-based tests for Alzheimer’s disease work by measuring the amount of certain proteins in the bloodstream — most notably amyloid-beta and tau. While these tests have represented important advances in recent years, they capture only part of the picture.
In Alzheimer’s disease, proteins don’t just accumulate — they misfold. The three-dimensional structure of proteins breaks down as the disease progresses, fundamentally altering how cells function. Until now, capturing these structural changes in a routine blood test had been largely out of reach.
“Most Alzheimer’s blood tests measure how much of an Alzheimer’s-linked protein is present,” the NIH explained in its announcement. But the new research suggests that what a protein looks like — its shape and configuration — may be just as diagnostically important as how much of it is circulating in the blood.
How the New Test Works
Researchers at The Scripps Research Institute in La Jolla, California, led by Dr. John Yates, analyzed blood plasma samples from 520 individuals — including people with diagnosed Alzheimer’s disease, people with mild cognitive impairment (MCI), and cognitively healthy controls. Participants were drawn from NIA-funded Alzheimer’s Disease Research Centers in Kansas and California.
The team used a powerful combination of mass spectrometry — a technique that can identify molecular masses and structures with extraordinary precision — and machine learning algorithms to detect subtle structural changes in proteins circulating in the blood.
The result was a three-protein diagnostic panel consisting of:
- C1QA — a component of the complement immune system
- CLUS (clusterin) — a protein involved in protein folding and cell death regulation
- ApoB — a lipoprotein involved in cholesterol transport
Together, these three proteins — identified by their structural configurations, not just their levels — were able to accurately distinguish between Alzheimer’s disease, mild cognitive impairment, and healthy controls. The panel could also differentiate disease stages and track how the disease progressed over time in individual patients.
Unlocking Earlier Detection and Sex Differences
One of the most compelling aspects of the study is what the structural approach revealed about sex differences in Alzheimer’s biology. Nearly all individuals with Alzheimer’s develop neuropsychiatric symptoms — behavioral and psychological changes including depression, anxiety, agitation, and hallucinations — but research has long noted that these symptoms often differ between males and females in frequency and severity.
By analyzing structural protein changes, the researchers observed distinct structural patterns by sex, offering clues about the underlying biological processes driving these differences. This finding could have important implications for personalized treatment strategies going forward.
The test also detected changes associated with variants of the ApoE gene — the strongest genetic risk factor for late-onset Alzheimer’s disease. Individuals carrying the ApoE ε4 allele face up to four times the risk of developing Alzheimer’s compared to those without it, and being able to detect protein structural changes linked to this genetic risk could one day allow for earlier preventive interventions.
What Experts Are Saying
The scientific community has responded with cautious optimism. Dr. Richard Hodes, director of NIH’s National Institute on Aging, which funded the study, called the findings a major conceptual shift:
“This work introduces a fundamentally new, blood-based approach to detecting and staging Alzheimer’s disease. By revealing protein structural changes associated with genetic risk, symptom severity, and sex differences — features not captured by existing biomarkers — this research could enable earlier diagnosis and more effective clinical trials.”
Dr. Yates echoed the potential: “This approach accurately distinguishes stages of the disease, meaning that it could help enable earlier diagnosis.”
Importantly, earlier diagnosis could be transformative. Many Alzheimer’s researchers believe the greatest opportunity for therapeutic intervention lies in the preclinical phase — the decade or more before symptoms emerge — when the brain still has the capacity to compensate and when treatments may be most effective.
Why Earlier Detection Matters
Alzheimer’s disease affects an estimated 6.9 million Americans aged 65 and older, according to the Alzheimer’s Association, and that number is projected to nearly double by 2060. Globally, the World Health Organization estimates that more than 55 million people live with dementia, of which Alzheimer’s is the most common form.
Despite billions invested in drug development, clinical trials for Alzheimer’s treatments have faced an alarming failure rate — in part because many trials enroll participants whose disease has already progressed too far. A reliable blood test that can detect the disease earlier and stage it more precisely could drastically improve clinical trial design and, ultimately, the chances of finding effective treatments.
Beyond drug development, earlier detection could also allow individuals and their families more time to:
- Plan financially and legally for future care needs
- Engage in lifestyle interventions that research suggests may slow cognitive decline
- Participate in clinical trials while in earlier disease stages
- Access emerging therapies that are most effective early in the disease course
What This Means for the Future of Alzheimer’s Diagnosis
While the findings are promising, it’s important to note that this research is still in the early stages. The study was conducted in a relatively controlled research setting, and the diagnostic panel would need to be validated in larger, more diverse populations before it could be considered for widespread clinical use.
Mass spectrometry, the core technology enabling this test, is also currently more complex and expensive than standard lab tests. However, the researchers suggest that as the technology matures and becomes more accessible, the cost and complexity barriers are likely to decrease.
The study was supported by NIA grants and represents a collaborative effort between The Scripps Research Institute and NIA-funded Alzheimer’s Disease Research Centers. The findings have been published in Nature Aging, one of the most prestigious peer-reviewed journals in the field of aging research.
Key Takeaways
- A new NIH-funded study identifies blood-based biomarkers that detect Alzheimer’s by measuring protein structural changes, not just protein levels.
- Using mass spectrometry and machine learning, researchers developed a three-protein panel (C1QA, CLUS, ApoB) that can distinguish Alzheimer’s from MCI and healthy aging.
- The test also reveals sex-specific differences in disease biology and detects changes linked to ApoE genetic risk.
- Earlier, more accurate diagnosis could transform clinical trials and open windows for earlier intervention.
- Further validation in larger, more diverse populations is needed before clinical adoption.
If you have concerns about your cognitive health or family history of Alzheimer’s disease, speak with your healthcare provider about available screening options and what they may mean for your individual risk profile.
Disclosure: This content is for informational purposes only and is not medical advice. Always consult a qualified healthcare provider before making changes to your health regimen.